Baiyunshan Pharma's Unit Gets Regulatory Nod to Amend License

MT Newswires Live

2025/03/06

Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical, obtained the Guangdong Provincial Drug Administration's approval to amend its license, according to a Shanghai Stock Exchange disclosure on Wednesday.

The changes included amending the production address to Xiahengtian Industrial Zone, Shayong Village, Lishui Town, Nanhai District, Foshan City, China from No. 1, Jiantashan Road, Huangpu District, Guangzhou, China. The scope of the production was also lessened, the pharmaceutical company said.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2517049669"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517049669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517049669?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 12:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517049669","market":"fut","top_or_hot":-1,"title":"Baiyunshan Pharma's Unit Gets Regulatory Nod to Amend License","media":"MT Newswires Live","content":"<html><body><p> Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical, obtained the Guangdong Provincial Drug Administration's approval to amend its license, according to a Shanghai Stock Exchange disclosure on Wednesday.</p><p>The changes included amending the production address to Xiahengtian Industrial Zone, Shayong Village, Lishui Town, Nanhai District, Foshan City, China from No. 1, Jiantashan Road, Huangpu District, Guangzhou, China. The scope of the production was also lessened, the pharmaceutical company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Pharma's Unit Gets Regulatory Nod to Amend License</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Pharma's Unit Gets Regulatory Nod to Amend License\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-06 12:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical, obtained the Guangdong Provincial Drug Administration's approval to amend its license, according to a Shanghai Stock Exchange disclosure on Wednesday.</p><p>The changes included amending the production address to Xiahengtian Industrial Zone, Shayong Village, Lishui Town, Nanhai District, Foshan City, China from No. 1, Jiantashan Road, Huangpu District, Guangzhou, China. The scope of the production was also lessened, the pharmaceutical company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517049669","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517049669","pubTimestamp":1741235563,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Baiyunshan Pharmaceutical's  subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical, obtained the Guangdong Provincial Drug Administration's approval to amend its license, according to a Shanghai Stock Exchange disclosure on Wednesday.The changes included amending the production address to Xiahengtian Industrial Zone, Shayong Village, Lishui Town, Nanhai District, Foshan City, China from No. 1, Jiantashan Road, Huangpu District, Guangzhou, China. The scope of the production was also lessened, the pharmaceutical company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK1191":"制药","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK0097":"医药电商","BK0070":"员工持股","BK1606":"中医药概念","00874":"白云山","BK0028":"国家队","BK1197":"保健护理产品经销商","BK0239":"医药制造","BK0183":"MSCI概念","BK0196":"行业龙头","BK0012":"证金概念","BK0188":"融资融券","BK0096":"民营医院","BK0175":"白马股"},"translate_title":"白云山制药子公司获得监管部门批准修改许可证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9,"00874":0.9},"content_text":"Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical, obtained the Guangdong Provincial Drug Administration's approval to amend its license, according to a Shanghai Stock Exchange disclosure on Wednesday.The changes included amending the production address to Xiahengtian Industrial Zone, Shayong Village, Lishui Town, Nanhai District, Foshan City, China from No. 1, Jiantashan Road, Huangpu District, Guangzhou, China. The scope of the production was also lessened, the pharmaceutical company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}